LLY

1,016.04

+3.16%↑

JNJ

229.09

+0.3%↑

ABBV

213.3

+2.38%↑

UNH

392.24

+1.34%↑

AZN

185.16

+0.81%↑

LLY

1,016.04

+3.16%↑

JNJ

229.09

+0.3%↑

ABBV

213.3

+2.38%↑

UNH

392.24

+1.34%↑

AZN

185.16

+0.81%↑

LLY

1,016.04

+3.16%↑

JNJ

229.09

+0.3%↑

ABBV

213.3

+2.38%↑

UNH

392.24

+1.34%↑

AZN

185.16

+0.81%↑

LLY

1,016.04

+3.16%↑

JNJ

229.09

+0.3%↑

ABBV

213.3

+2.38%↑

UNH

392.24

+1.34%↑

AZN

185.16

+0.81%↑

LLY

1,016.04

+3.16%↑

JNJ

229.09

+0.3%↑

ABBV

213.3

+2.38%↑

UNH

392.24

+1.34%↑

AZN

185.16

+0.81%↑

Home・Akcijų sąrašas・United Therapeutics Corp

United Therapeutics Corp

Atidarymo kaina

SektoriusSveikatos priežiūra

568.58 0.54

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

560.01

Max

571.22

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-89M 275M
Pardavimai	-8.7M 782M
P/E Sektoriaus vid.	20.882 51.415
Pelnas, tenkantis vienai akcijai	5.82
Pelno marža	35.176
Darbuotojai	1,400
EBITDA	-176M 348M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+14.16% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-07-29

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-476M 24B
Ankstesnė atidarymo kaina	568.04
Ankstesnė uždarymo kaina	568.58

Naujienos nuotaikos

By Acuity

46%

54%

145 / 345 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

292.345 / 309.245 Palaikymas ir pasipriešinimas

United Therapeutics Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-18 23:10; UTC

Karštos akcijos

Stocks to Watch: Agilysys, XP

2026-05-18 18:44; UTC

Pagrindinės rinkos jėgos

Claritev Shares Recover After Comments About DOJ

2026-05-18 23:55; UTC

Uždarbis

Review & Preview: Earnings' Last Gasp -- Barrons.com

2026-05-18 23:47; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-18 23:47; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

2026-05-18 23:37; UTC

Rinkos pokalbiai

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

2026-05-18 22:31; UTC

Įsigijimai, susijungimai, perėmimai

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

2026-05-18 22:30; UTC

Įsigijimai, susijungimai, perėmimai

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

2026-05-18 22:30; UTC

Įsigijimai, susijungimai, perėmimai

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

2026-05-18 22:25; UTC

Įsigijimai, susijungimai, perėmimai

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

2026-05-18 22:24; UTC

Įsigijimai, susijungimai, perėmimai

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

2026-05-18 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-18 20:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2026-05-18 20:25; UTC

Uždarbis

Correct: XP 1Q Total Client Assets BRL1.53T

2026-05-18 20:23; UTC

Uždarbis

XP 1Q Total Client Assets BRL1.53B

2026-05-18 20:19; UTC

Uždarbis

XP 1Q Adj EPS BRL2.49 >XP

2026-05-18 20:19; UTC

Uždarbis

XP 1Q Rev BRL4.73B >XP

2026-05-18 19:10; UTC

Rinkos pokalbiai

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

2026-05-18 19:00; UTC

Uždarbis

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

2026-05-18 18:52; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

2026-05-18 18:17; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

2026-05-18 17:22; UTC

Rinkos pokalbiai

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

2026-05-18 16:57; UTC

Įsigijimai, susijungimai, perėmimai

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

2026-05-18 16:57; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2026-05-18 16:57; UTC

Rinkos pokalbiai

Commodities Higher as Traders Want Physical Assets -- Market Talk

2026-05-18 16:54; UTC

Įsigijimai, susijungimai, perėmimai

Vinci Doesn't Set Out Financial Details of Deal

2026-05-18 16:50; UTC

Įsigijimai, susijungimai, perėmimai

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

2026-05-18 16:49; UTC

Įsigijimai, susijungimai, perėmimai

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

2026-05-18 16:49; UTC

Įsigijimai, susijungimai, perėmimai

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

2026-05-18 16:48; UTC

Įsigijimai, susijungimai, perėmimai

Vinci Buys Canada's Modern Group of Companies

Akcijų palyginimas

Kainos pokytis

United Therapeutics Corp Prognozė

Kainos tikslas

By TipRanks

14.16% į viršų

12 mėnesių prognozė

Vidutinis 649.08 USD 14.16%

Aukščiausias 738 USD

Žemiausias 516 USD

Remiantis 13 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines United Therapeutics Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

13 ratings

Pirkti

Laikyti

Parduoti

Remiantis 13 analitikų, pateikusių United Therapeutics Corp akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

292.345 / 309.245Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

145 / 345 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.